Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett King

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|November 29, 2023
Inhibition of T-cell activity in alopecia areata: recent developments and new directionsThierry Passeron, Brett King, Julien Seneschal, et al.
American Journal of Clinical Dermatology|April 11, 2025
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of TreatmentBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
Journal of the American Academy of Dermatology|April 1, 2022
Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areataBrett King, Natasha Mesinkovska, Paradi Mirmirani, et al.
American Journal of Clinical Dermatology|March 31, 2026
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical StudiesMaryanne Senna, Jennifer Soung, Ignasi Figueras, et al.
The British Journal of Dermatology|September 14, 2023
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trialsBrett King, Jerry Shapiro, Manabu Ohyama, et al.
The British Journal of Dermatology|October 21, 2024
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areataMelissa Piliang, Jennifer Soung, Brett King, et al.
The Journal of Clinical Investigation|November 3, 2025
Cellular profiling identifies targetable T cell phenotypes in lymphocytic variant hypereosinophilic syndromeKristy Tefft, Amy Wang, Zachary Z Reinstein, et al.
Dermatology and Therapy|October 14, 2025
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia AreataBrett King, Amy McMichael, Rodney Sinclair, et al.
The British Journal of Dermatology|April 20, 2022
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitisEric L Simpson, Robert Bissonnette, Amy S Paller, et al.
Journal of the American Academy of Dermatology|March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week resultsBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|November 29, 2023
Inhibition of T-cell activity in alopecia areata: recent developments and new directionsThierry Passeron, Brett King, Julien Seneschal, et al.
American Journal of Clinical Dermatology|April 11, 2025
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of TreatmentBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
Journal of the American Academy of Dermatology|April 1, 2022
Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areataBrett King, Natasha Mesinkovska, Paradi Mirmirani, et al.
American Journal of Clinical Dermatology|March 31, 2026
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical StudiesMaryanne Senna, Jennifer Soung, Ignasi Figueras, et al.
The British Journal of Dermatology|September 14, 2023
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trialsBrett King, Jerry Shapiro, Manabu Ohyama, et al.
The British Journal of Dermatology|October 21, 2024
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areataMelissa Piliang, Jennifer Soung, Brett King, et al.
The Journal of Clinical Investigation|November 3, 2025
Cellular profiling identifies targetable T cell phenotypes in lymphocytic variant hypereosinophilic syndromeKristy Tefft, Amy Wang, Zachary Z Reinstein, et al.
Dermatology and Therapy|October 14, 2025
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia AreataBrett King, Amy McMichael, Rodney Sinclair, et al.
The British Journal of Dermatology|April 20, 2022
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitisEric L Simpson, Robert Bissonnette, Amy S Paller, et al.
Journal of the American Academy of Dermatology|March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week resultsBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Pageof 8